Biochemical Assessment of Risk Factors in Coronary Artery Disease (CAD) Patients: A Comprehensive Review

Coronary artery disease (CAD) remains one of the leading causes of mortality and morbidity worldwide. The disease primarily develops due to atherosclerosis, a chronic inflammatory condition characterized by endothelial dysfunction, lipid accumulation, oxidative stress, thrombosis, and vascular inflammation. Biochemical markers play a crucial role in the early diagnosis, risk stratification, prognosis, and therapeutic monitoring of CAD. This review comprehensively evaluates traditional and emerging biochemical risk factors associated with CAD, including lipid profile abnormalities, inflammatory markers, cardiac biomarkers, glycemic indicators, renal biomarkers, coagulation factors, electrolytes, and novel genetic markers. Traditional lipid parameters such as low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, and total cholesterol remain central to cardiovascular risk assessment. Inflammatory markers including high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) provide insight into vascular inflammation and plaque instability. Cardiac biomarkers such as troponins, CK-MB, BNP, and NT-proBNP are essential for myocardial injury detection and prognosis. Emerging biomarkers including lipoprotein(a), homocysteine, genomic markers, and omics-based approaches are increasingly contributing to personalized cardiovascular medicine. The review also discusses current risk prediction models, limitations of biomarker interpretation, controversies in clinical application, and future perspectives involving artificial intelligence and precision medicine. Current evidence supports a multi-marker approach integrating biochemical, clinical, imaging, and genetic data for comprehensive CAD management.

Coronary artery disease, atherosclerosis, biochemical markers, lipid profile, hs-CRP, troponin, HbA1c, inflammation, cardiovascular risk assessment.

1. Libby P. The changing landscape of atherosclerosis. Nature. 2021;592(7855):524–533. [Google Scholar] [Crossref]

2. World Health Organization. Cardiovascular Diseases (CVDs). Geneva: WHO; 2024. [Google Scholar] [Crossref]

3. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695. [Google Scholar] [Crossref]

4. Ross R. Atherosclerosis—an inflammatory disease. N Engl J Med. 1999;340(2):115–126. [Google Scholar] [Crossref]

5. Lusis AJ. Atherosclerosis. Nature. 2000;407(6801):233–241. [Google Scholar] [Crossref]

6. Ridker PM. Inflammation in atherosclerosis. Circulation Research. 2014;114(12):212–226. [Google Scholar] [Crossref]

7. Falk E. Pathogenesis of atherosclerosis and plaque disruption. Circulation. 1995;92(3):657–671. [Google Scholar] [Crossref]

8. Grundy SM. Cholesterol and coronary heart disease. JAMA. 1986;256(20):2849–2858. [Google Scholar] [Crossref]

9. Ference BA, et al. LDL cholesterol and cardiovascular disease. Eur Heart J. 2017;38(32):2459–2472. [Google Scholar] [Crossref]

10. Miller M, et al. Triglycerides and cardiovascular disease. Circulation. 2011;123(20):2292–2333. [Google Scholar] [Crossref]

11. Ridker PM. High-sensitivity C-reactive protein and cardiovascular risk. Circulation. 2003;107(3):363–369. [Google Scholar] [Crossref]

12. Ridker PM, et al. Interleukin-6 and cardiovascular disease. Circulation. 2000;101(15):1767–1772. [Google Scholar] [Crossref]

13. Popa C, et al. TNF-alpha in chronic inflammatory conditions. Cytokine Growth Factor Rev. 2007;18(6):451–466. [Google Scholar] [Crossref]

14. Thygesen K, et al. Fourth universal definition of myocardial infarction. Circulation. 2018;138(20): e618–e651. [Google Scholar] [Crossref]

15. Apple FS. Clinical and analytical evaluation of cardiac biomarkers. Clin Chim Acta. 1999;284(2):151–161. [Google Scholar] [Crossref]

16. Maisel AS. BNP in cardiovascular disease. Lancet. 2002;359(9307):316–322. [Google Scholar] [Crossref]

17. Emerging Risk Factors Collaboration. Diabetes mellitus and cardiovascular disease. Lancet. 2010;375(9733):2215–2222. [Google Scholar] [Crossref]

18. Matthews DR, et al. Homeostasis model assessment. Diabetologia. 1985;28(7):412–419. [Google Scholar] [Crossref]

19. Alberti KG, et al. Harmonizing the metabolic syndrome. Circulation. 2009;120(16):1640–1645. [Google Scholar] [Crossref]

20. Wald DS, et al. Homocysteine and cardiovascular disease. BMJ. 2002;325(7374):1202. [Google Scholar] [Crossref]

21. Tsimikas S. Lipoprotein(a) and cardiovascular disease. N Engl J Med. 2017;377(1):78–79. [Google Scholar] [Crossref]

22. Inouye M, et al. Genomic risk prediction of coronary artery disease. Nat Genet. 2018;50(9):1219–1224. [Google Scholar] [Crossref]

23. Go AS, et al. Chronic kidney disease and cardiovascular risk. N Engl J Med. 2004;351(13):1296–1305. [Google Scholar] [Crossref]

24. Gerstein HC, et al. Microalbuminuria and cardiovascular risk. JAMA. 2001;286(4):421–426. [Google Scholar] [Crossref]

25. Ernst E. Fibrinogen as a cardiovascular risk factor. Ann Intern Med. 1993;118(12):956–963. [Google Scholar] [Crossref]

26. Danesh J, et al. D-dimer and cardiovascular disease. Circulation. 2001;103(19):2323–2327. [Google Scholar] [Crossref]

27. Vaughan DE. PAI-1 and thrombosis. Arterioscler Thromb Vasc Biol. 2005;25(1):1–7. [Google Scholar] [Crossref]

28. Goyal A, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307(2):157–164. [Google Scholar] [Crossref]

29. Del Gobbo LC, et al. Magnesium and cardiovascular disease. Am J Clin Nutr. 2013;98(1):160–173. [Google Scholar] [Crossref]

30. Feig DI, et al. Uric acid and cardiovascular risk. N Engl J Med. 2008;359(17):1811–1821. [Google Scholar] [Crossref]

31. D’Agostino RB, et al. General cardiovascular risk profile for use in primary care. Circulation. 2008;117(6):743–753. [Google Scholar] [Crossref]

32. Arnett DK, et al. 2019 ACC/AHA guideline on primary prevention of cardiovascular disease. Circulation. 2019;140(11): e596–e646. [Google Scholar] [Crossref]

33. Johnson KW, et al. Artificial intelligence in cardiology. J Am Coll Cardiol. 2018;71(23):2668–2679. [Google Scholar] [Crossref]

• In Silico Safety Evaluation of Local Spices Tea Used Against Human Metapneumovirus (HMPV)
• Assessment of Genotoxicity and Inflammation in the Brain Hippocampus of Lead-Induced Mice Treated With Diospyros Mespiliformis
• Determination of Polycyclic Aromatic Hydrocarbons and Total Petroleum Hydrocarbons in Crude Polluted Soil from Esaba, Ughelli South, Delta Nigeria
• Lipase Derived from Bacteria Isolated from The Seawater of Muara Badak, East Kalimantan
• "The Interplay Between Nutritional Deficiencies and Susceptibility to Mycotoxicosis: Implications for Public Health and Food Safety"